Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described 5-fluoro-7h-pyrrolo[2,3-d] pyrimidine compounds as Wee1-like protein kinase (Wee1) inhibitors potentially useful for the treatment of cancer.